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MHC class I genes encode transplantation antigens thatareessential for recogni-
tion offoreign antigens by T cells. Expression ofclassical MHC class I genes is de-
velopmentally controlled. Low levels ofclass I message and surface antigens become
detectable only after the mid-somite stage in mouse embryogenesis (1, 2). MHC
class I expression remains very low during gestation, but increases sharply in most
organs after birth and during the first 2 wk ofpostnatal development (3). In adults,
the majority ofsomatic cells express MHC class I genes except for those in the cen-
tral nervous system (4, 5). Class I genes can be induced by lymphokines such as
IFNs (6) and TNF (7) that modulate immune responses.
Transcription oftheclass I gene is controlled by the conserved cis-acting sequence
designated class I regulatory element (CRE)', which is present in the upstream re-
gion ofthe MHC class I gene (8-10). The CRE isjuxtaposed to anotherregulatory
element, the IFN consensus sequence(ICS)(11), which isresponsiblefor IFN-mediated
induction ofthe class I gene (12-14). The CRE elicits an enhancer like function in
tissue culture fibroblasts (8-10). In undifferentiated F9 embryonal carcinoma cells,
however, the CREnegativelyregulates transcriptionofthe class I gene (9). TheCRE
acts neither negatively nor positively in cells derived from mid- to late-somite stage
embryos (15). These findings indicate that the CRE is involved in developmental
regulation of the class I gene expression.
By analogy with other systems (16, 17), the CRE is expected to control transcrip-
tion ofthe class I gene by interacting with trans-acting nuclear proteins. Indeed, the
CRE was found to contain three discrete sequences (region I, II, and III; Fig. 3)
that bind different nuclear proteins present in a number ofcultured cell lines (10,
18, 19). These regions correspond to direct and inverted repeats in the CRE (19).
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The present study was undertaken to delineate the basis of developmental and
tissue-specific expression of the class I genes in vivo. We first examined various de-
veloping and adult murine tissues for the presence of nuclear proteins that bind the
CRE. Then we assessed the functional significance of factor binding to each region
of the CRE by site-directed mutagenesis in cultured fibroblasts. Our results show
that nuclear factors capable of binding to the CRE are expressed in vivo in correla-
tion with developmental and tissue-specific expression of the MHC class I gene. In
addition, we show that both region I and region II of the CRE are capable of posi-
tively regulating class I gene transcription.
Materials and Methods
Nuclear Extract Preparation.
￿
Nuclear extracts from mouse LH8 Tcells and Ltk- fibroblasts
were prepared accordingto Dignam et al. (20) with modifications(19). Nuclearextracts from
tissues were prepared accordingto Gorski et al. (21) with minormodifications. Briefly, tissues
obtained from BALB/c mice (NIH Small Animal Section) were homogenized in homogeni-
zation buffer and centrifuged at 23,000 rpm for 30 min. Crude nuclear pellets were cen-
trifuged again througha 10-mlcushion of a9:1 mixtureof homogenization buffer andglycerol.
The nuclear pellets were then lysed in lysing buffer followed by extraction with 4 M ammo-
nium sulfate. Extracted proteins were precipitated by adding solid ammonium sulfate, and
the precipitates were dialyzed extensively in dialysis buffer. Allthe buffers contained the pro-
tease inhibitors PMSF (0.1 mM)and aprotinin (0.1%) (Sigma Chemical Co., St. Louis, MO).
Oligonucleolides.
￿
Alloligonucleotides were synthesized in an automated synthesizer (Coder
300; Vega Biotechnologies, Inc., Tucson, AZ); purified by HPLC, andannealed as described
(19). The following duplex oligonucleotides were used as probes or competitors. The CRE
spanning from nucleotide position -203 to -161, region I (from -173 to -161), region II
(from -203 to -185) (see Fig. 4), and the ICS (from -167 to -139, reference 19) of the
H-2L d gene. Additionally a 70-bp human metallothionein IIA (hMTIIA) sequence con-
taining an AP-1 site (22),
5'GCGCGGCCGGGTGTTTCGCCTGGAGCCGC-
AAGTGACTCAGCGCGGGGCGTGTGCAGGCA3'
and an AP-1 recognition site of the SV40 gene (23),
5'CAATTAGTCAGCAACCATA 3'
were used.
Gel Mobility Shift Assay.
￿
Bindingof nuclear proteins to theCRE was studied by a gelmo-
bility shift assay (19). A 114-bp Pst I-Ava II fragment of the mouse H-2L" gene containing
the CRE and ICS as well as oligonucleotides corresponding to region I and region II were
end-labeled with ,y-["P]ATP usingT4 polynucleotide kinase. The ICS probe was prepared
as described (24). These probes (0.1-0.6 ng DNA containing 5,000 to 15,000 cpm) were in-
cubated with 3-5 ttg of nuclear extract proteins in the presence of 1.5-4.0 Wg poly(dI-dC)
(Pharmacia Fine Chemicals, Piscataway, NJ) for 15-30 min at 0°C or room temperature
and electrophoresed through a 3.4 or 4% polyacrylamide gel. In some experiments binding
reactionswere carried out in the presence of additional protease inhibitors (1 UM leupeptin
and 1 ttM pepstatin). Competition by mutant oligomers was tested by adding 10-40 ng of
double-stranded oligomers to the reaction mixture.
Site-directed Mutogenesis.
￿
Site-directed mutagenesis wasperformed as described (25). A 400-
bp Xba I-Hind III fragment that contained in 5' upstream region of the H-2Id gene in-
cluding TATA and CAT boxes and the CRE and ICS was cloned into M13 mp18 . 20-21-bp
long mutant oligomers, each containing asingle 2-bp substitution, were annealed to the tem-BURKE ET AL .
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plate, and were extended and ligated by the Klenow fragment of DNA polymerase I and
T4 DNA lipase in the presence of a thionucleotide, dCTPceS (Amersham Corp., Arlington
Heights, IL) . The resultant heteroduplexes were digested with Nci I, followed by exonuclease
III treatment, which removes the wild-type template. The remaining sequences were poly-
merized and ligated in the presence ofdeoxynucleotides . Mutant phage DNAs were sequenced
by the Sanger method to confirm accurate mutagenesis . The efficiency of mutagenesis by
this procedure was -80%. To construct mutant pL" CAT genes, the mutant Xba I-Hind
III fragments were then inserted into the Xba I-Hind III site of pL" CAT 1.4K (9) .
ChloramphenicolAcetyl Transferase (CAT) Assay .
￿
Transient CAT assays were performed with
Ltk - fibroblasts using the calcium phosphate precipitation method with BES buffer (26), pH
6.95 (9, 27) . Briefly, a mixture ofDNA (4 jug ofCAT constructs, 2 Wg ofpCH 110 (281 that
contains the lacZ gene under the control of the SV40 promoter, and 14 jig of carrier DNA
pUC19) was added to 5 x 10' Ltk - cells and incubated for 16 h . Cells were then washed with
PBS and incubated further in medium with or without murine IFN-cr/0 (800 U/ml) (Lee
Biomolecular, San Diego, CA) for an additional 12-14 h . CAT and 0-galactosidase activities
were measured using equal amounts of extracted protein obtained from each sample . Pro-
moter activity elicited by mutant CRE was assessed after normalizing transfection efficiency
ofeach sample by dividing counts of acetylated chloramphenicol by 0-galactosidase activity.
Results
Nuclear Proteins that Bind to the CRE Are Present in Developing and Adult Murine
Tissues . The CRE encompasses position -161 to -203 relative to the RNA start
site, and elicits positive and negative transcriptional regulation (8, 9) . Israel et al .
(18), Baldwin and Sharp (10), and Singh et al . (29)showed that specific nuclear pro-
teins interact with this sequence . We showed that there are three independent se-
quences (region I, II, and III ; Fig. 3, diagram) in the CRE that bind distinct nuclear
proteins in most tissue culture cells (19) .
In an effort to discern functional roles of the CRE for class I gene expression in
vivo, we examined various developing and adult tissues for the presence or absence
ofCRE binding factors in gel mobility shift assays . In the first series of experiments
a "P-labeled probe containing the entire CRE of the H-21d gene was used . Results
of adult tissue extracts are shown in Fig. 1 A . Extracts from liver and spleen revealed
a single retarded band, while those of brain had a doublet, all ofwhich migrated
essentially the same distance in the gel . The single band and the doublet were com-
peted with an excess of unlabeled oligonucleotide corresponding to the entire 40-bp
CRE (Fig . 1 A, lanes 3, 10, and 17), but not the ICS (lanes 7, 14, and 21), indicating
that the retarded species represents factor binding to the CRE . Protease treatment
of nuclear extracts from these tissues eliminated the retardedband (data not shown),
indicating that the factor(s) is a protein(s) . To analyze binding sites further, compet-
itor oligomers corresponding to region I and region II were added to reaction mix-
tures . When these competitors were added independently to liver extracts, even at
50 times molar excess, the retarded band was not eliminated (lanes 4, 5) . However,
this band was readily competed when the two oligomers were added together at 10
times molar excess . Hence, it is likely that the band seen in liver extracts consists
of two binding activities, one representing binding to region I and the other to re-
gion II, both ofwhich migrate the same distance in the gel . The retarded band seen
in spleen extracts was almost completely competed by the region I oligomer, leaving
only a weak residual band (lane 18) . Addition of the region II competitor increased
the intensity of the band (lane 19), the basis ofwhich has not investigated . However,131 2
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FIGURE 1 .
￿
Identification of nuclear factors that bind
the CRE in adult (A) and developing (B) tissues in
vivo . Gel mobility shift experiments were carried out
with a 32P-labeled Pst I-Ava II fragment that con-
tains theCRE and ICS using 3-5 Rg ofnuclear ex-
tract proteins prepared from BALB/c tissues . To de-
termine specificity andsubregions offactor binding,
double-stranded oligonucleotides corresponding to
theCRE, region Iand region II, and ICSwere added
to reaction mixtures at -20 times molar excess .
When competitors for region I and II are added to-
gether, -10 timesmolar excess ofeach oligomer was
used .
a combination of region I and region II competitors eliminated the band entirely
(lane 20), indicating that spleen extracts have a relatively high region I binding ac-
tivity and a low region II activity . In contrast, brain extracts generated a doublet
that was completely competed by region II oligomer alone (lane 12) . Addition of
region I competitor did not remove the doublet . These results indicate that brain
extracts do not contain a protein that binds to region I, but contain a region II binding
protein(s) . The mixing of spleen and brain extracts did not eliminate a band com-
petable by the region I competitor (not shown) . Fig . 1 B shows gel mobility shift
patterns of extracts from developing liver, i.e ., from fetus (day 19 of gestation), neo-
nates (day 0), and 7-d-old mice . We tested these tissues to see if developmental regu-
lation of class I genes (1, 3) correlates with CRE binding activities . Extracts from
developing liver showed a single retarded band that can be competed by the entire
CRE . The upper broad band seen in extracts of fetuses and neonates on the day
of birth was nonspecific, since neither CRE nor ICS competitor removed it . The
lowerband seen with fetal liver extracts was completely eliminated by region II oligomer
(Fig . 1 B, lane 5), whereas region I oligomer did not affect the retarded band . In
rare cases, the band from fetal liver extracts had a very minor component competed
by region I oligomer, suggesting occasional low expression of region I protein during
gestation . Extracts from younger fetuses (day 17 and day 18 of gestation) also re-
vealed a band competable only by region II (data not shown) . In contrast, the band
from neonatal and day 7 mice was not competable by either region I or region II
oligomer alone (lanes 9, 10, 14, 15) . As was the case for adult liver and spleen (Fig .
1 A), competition was attained after addition ofboth oligomers (lane 11, 16) . Hence
during gestation region I binding protein appears to be very low or absent, but it
increases rapidly following birth .
The Use of Region specific Probes Confirms the Correlation between Region I Binding and
Class I Gene Regulation In Vioo. To extend the observations described above we used
two probes that separate regions I and II of the CRE . These probes were used to
test whether there are additional binding activities that are not detected with theBURKE ET AL.
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probe covering the entire CRE used in the preceding section . In some cases probes
encompassing shortersequences can reveal binding activities not readily foundwith
longer probes (24, 30) . In addition, these probes allowed us to examine whether
binding of region I and region II occur independently of each other. Results of ex-
tracts obtained with adult tissues (A) and developing liver (B) are shown in Fig . 2 .
The region I probe encompassing the nucleotide stretch from -173 to -161 of the
CRE (see Fig . 4) elicited a broad single band or doublet in adult spleen and liver
extracts . These retarded species were competed by the region I competitor but not
by the region II competitor. In contrast, in brain extracts region I probe did not
generate a detectable band . These data indicate that spleen and liver, but not brain
extracts have aregion I binding activity, and confirm the results seen with theCRE
probe in Fig . 1 A . Further, these data show that the region I binding activity can
be detected independently of region II . The region II probe encompassing nucleo-
tides -203 to -185 of theCRE (see Fig . 4) generated two closely migrating bands
in adult liver and in brain extracts, which were specifically competed by the region
II oligomer. The region II probe didnot reveal an appreciable binding activity with
spleen extracts . These data indicate that region II binding activity is present abun-
dantly in liver and brain, but at a very reduced level in spleen, in agreement with
the results presented in Fig . 1 A . Thus, binding activities to region I and region
II are independent of each other, and the lack of region I binding activity seen in
FIGURE 2 .
￿
Binding offactors to region
I and region II of the CRE . Gel mo-
bility shift experiments were carried
out with 12p-labeled oligonucleotide
probes corresponding to region I orre-
gion II oftheCRE (see the top of the
figure) . Unlabeled competitor oligo-
mers were added to reaction mixture
at 20-50 times molar excess (see the
bottom offigure) . (A) Adult tissue ex-
tracts, (B) fetal (day 19 ofgestation) and
neonatal liver extracts. AP-1-1 ; hMTIIA
competitor (22); AP-1-2 ; the AP-1 se-
quence in the SV40 promoter (23) .131 4
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brain extracts was not caused by region II binding. We observed the formation of
doublets with some probes (see Fig. 1 A, brain; Fig. 2 A, liver and brain), the basis
of which is not entirely clear. It may reflect the heterogeneity of binding proteins
possibly caused by post-translational modifications, such as phosphorylation (31).
Fig. 2 B depicts results with fetal and neonatal liver extracts. Consistent with the
data in Fig. 1 B, the region I probe did not generate a band from fetal liver extracts,
while the region II probe elicited two closely spaced bands competed by the region
II competitor, similar to those seen with adult tissues (Fig. 2 A). Neonatal extracts,
on the other hand, showed a weak but reproducible band with the region I probe.
This band was specifically competed by the region I oligomer. These results are in
agreement with the data in Fig. 1 B and indicate that the region I binding activity
becomes detectable in correlation with the increase in class I expression during de-
velopment.
The AP-1 protein, a trans-acting factor for the SV40 control region as well as other
genes (22, 23), has been shown to bind to region 11 of mouse MHC class I genes
(23, 32). We tested whether the region II binding activity seen in our work represents
binding of AP-1. In Hela cell extracts, a 70-bp hMTIIA promoter containing an
AP-1 recognition site (22) generated several retarded bands that were competed by
the probe sequence itself and by the SV40 AP-1 site (see Materials and Methods).
We tested these sequences for their ability to compete for region II binding. As seen
in Fig. 2 B no competition was observed with either sequence. Competition was not
detected with adult tissues either (Fig. 2 A). In addition, using mouse extracts we
did not observe a specific band generated by hMTIIA, indicating that AP-1 binding
activity is low or absent in extracts we tested (not shown) . Thus, it is highly unlikely
that the region 11 binding activity detected in this study represents AP-1 binding.
The absence (or very low levels) of the region I binding activity in brain and fetal
liver extracts and of the region II binding activity in adult spleen was not due to
differential degradation of nuclear proteins: With the probe covering the ICS (19),
all tissues shown in Figs. 1 and 2 generated a single retarded band of the same mo-
bility, which was competed by the ICS oligomer, but not by the CRE oligomer (not
shown). Furthermore, the cfos enhancer probe generated the identical mobility shift
patterns in fetal and adult liver extracts (33). These results lend further credence
to the proposed correlation between region I binding and class I gene regulation in vivo.
We did not observe unequivocal binding of a factor to region III in any ofextracts
prepared from tissues, even though extracts from most tissue culture cell lines showed
a binding activity to region 111 (19; Hirschfeld, S., unpublished data). The basis
of this observation is not clear. Differences in the procedures of extract preparation
probably do not account for it, as spleen extracts prepared according to Dignam
et al . (20) showed no specific binding activity to region III either.
Functional Significance ofProtein Binding to Subregions of the CRE.
￿
The above study
suggested that protein binding to region I plays a role in positive regulation of the
class I gene. Therefore, we studied relative contributions of region I, II, and III
sequences to the enhancer-like activity in tissue culture cells (8-10). We used pLd
CAT 1 .4K (9) in which the CAT reporter gene is under the control of a 1.4-kb up-
stream region of the H-2Ld gene. This upstream region contained the CRE, ICS,
and the basic promoter region, and exerts positive regulation of class I gene tran-BURKE ET AL .
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FIGURE 3 .
￿
Competition by mutant CRE. Gelmo-
bility shift experiments were carried out with 8 ug
ofLH8 T cell nuclear extract proteins as described
(19). Wild-type or mutant oligomers, containing 2 by
substitutions, M72, M13, M14, M86 (Fig . 4), were
added at 20 timesmolar excess as shown at thebottom
of each lane . Reactions in lanes 5-10 were carried
out in the presence of region 11 oligomer at -10
times molar excess .
scription in fibroblasts (9, 15) . By site-directed mutagenesis single 2-bp substitu-
tions were introduced independently into regions I, 11, and III (Fig . 4) .
These mutants were first tested for their ability to bind the respective protein in
competition assays (Fig . 3) . Extracts from LH8 Tcells showed multiple retarded
bands 1, 11, and III . These bands represented protein binding to region I, II, and
III, respectively (19), and were competed by excess unlabeled CRE (lane 2) . Band
11, readily eliminated by the wild-type region 11 competitor oligomer, was not elimi-
nated by mutant M72 oligomer (lanes 3 and 4), indicating that M72 mutation
abrogates protein binding to region 11 . Lanes 5-10 show competition by region III
and region I mutants, which were tested in the presence of unlabeled wild-type re-
gion II oligomer. As expected, the wild-type region III oligomer (lane 6) removed
band III completely, and reduced the intensity of band 1 . M13 oligomer did not
compete for region III binding, but did compete for region I binding (lane 7) . M14
oligomer on the other hand, retained the ability to compete for region III binding
(lane 8), consistent with the previous methylation interference data, which indicated
that protein binding occurs in the rightand left halves but not in the center ofregion
111 (19) . As seen in lane 9, the wild-type region I oligomer removed band I without
significantly affecting band III binding activity . Addition of increased amounts of
region I competitor, however, did eliminate region III binding (data not shown) .
In contrast, the M86 mutant, which disrupts the inverted repeat of region 1, failed
to compete for band I (lane 10) . These results indicate the mutations M86, M72,
and M13 selectively abolish protein binding to region 1, 11, and III of the CRE,
respectively. Extracts from Ltk- cells gave similar results (data not shown) .
The ability of these mutant CRE to enhance transcription of the class I gene was
then tested with mutant pL'/CAT 1 .4K constructs (Fig. 4) in a transient CAT assay
with Ltk- fibroblasts . Results are shown in Table I . Control plasmid pLd CAT 123,
which does not have the CRE, yielded -10 times lower CAT activity than the wild-
type pL" CAT 1.4K. The higher CAT activity seen by pL' CAT 1AK is attributable
to the enhancer-like activity elicited by the CRE (8-10) . Mutant pLd CAT 1.4K
M86, which failed to bind region I in vitro, did not manifest enhancer-like activity131 6
￿
trans-ACTING PROTEINS OF THE MHC CLASS I GENE
PL° CAT 123Wr
￿
---H_F7 77
FIGURE 4.
￿
Mutant CAT constructs used for evaluation ofthe enhancer-like activity. The nucleotide
sequence of the CRE and its subregions is shown on top of the wild-type pLd CAT 1 .4K con-
struct (9, 24) that had the entire 1.4-kb upstream region of the H-2L' gene connected to the
reporterCAT gene. In mutants onlymutated nucleotides are shown. Solid line represents nucleotides
identical to the wild-type CRE. pLd CAT 123 had the promoter region containing TATA and
CAT boxes but lacked both the CRE and ICS.
fully. CAT activity by this mutant was consistently about half that of the wild-type
pLd CAT 1.4K . M72 mutation, which precluded protein binding to region 11 in
vitro also reduced the enhancer-like activity, but to a lesser extent (N30%) . The
reductions in transcriptional activity seen by these two mutants were statistically
significant (Table 1). In contrast, M13 mutation, which abrogated protein binding
to region III (but not regions I and 11), maintained full enhancer function. The
same was true for M14, which does not affect factor binding to any of the three regions.
This indicates that region I and II are capable ofpositively regulating class I genes,
presumably through the binding of specific proteins. In contrast, region III appears
to have no major role in exerting enhancer-like activity in Ltk- cells.
TABLE I
Mutations in the CRE Reduce the Enhance Activity
Constructs
pLd CAT 1 .4 K
pLd CAT 1 .4 K M72
pLd CAT 1 .4 K M13
pLd CAT 1 .4 K M14
pLd CAT 1 .4 K M86
pLd CAT 123
Transient CAT activity was measured in Ltk- cells treated with or without
IFN-a//3 (800 U/ml) for 12-14h. To adjust for variability of transfection efficiency,
CAT activity in each sample was normalized using (3-galactosidase activity elicited
by the cotransfected pCH110; this variability did not exceed 13% . Each value
represents a mean of four tests. Enhancer activity is the activity of pL'I CAT
I AK (and its mutants) divided by that of pLd CAT 123 . P value was derived
from a one-tail signs test using four independent experiments. NS, not significantly
different from pLd CAT 1 .4K. IFN response is estimated as CAT activity with
IFN divided by CAT activity without IFN for each construct. P*, IFN response
by all mutants were significantly higher than pLd CAT 123.
1 .4Kb
PLd CAT 1.4K WT
CLASS I REGULATORY ELEMENT
ICRE)
-203 -161
-7Q-
I""" .. """GCCAGGCGGTGAGGTCAGGGGTGGGGAAGCCCAGGGCTGGGGATTCCCCATCTCCT CAT
PLd CAT1AKM72 E".""."" 1
II
I TT """"" CAT
PL° CAT 1.4K M13 E-"""" .. TT ... .. . CAT
PLdCAT1AKM14 F-""""". AA """"" CAT
PL° CAT 1AKM86 ~""""" . CC """""" CAT
123
Enhancer activity (P)
IFN response
+ IFN/- IFN (P*)
9.8 (-) 3 .9 (>O.06)
6 .8 (>0.06) 2 .8 (>0.06)
11 .2 (NS) 4.4 (>0.06)
8 .9 (NS) 4.3 (>0.06)
5 .1 (>0.06) 2 .9 (>0.06)
1 .0 (>0.06) 1 .1 (-)BURKE ET AL.
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We also tested whether these mutations affect the ability to enhance class I gene
transcription in response to IFN. IFN induces class I gene transcription through
the conserved ICS (12-14), which partially overlaps the CRE. We found that the
ICS binds nuclear factors inducible by IFN, and that the protein binding to the
ICS is necessary for IFN-mediated transcriptional induction of the class I gene (30)
in fibroblasts. Additional evidence indicates that the CRE also participates in re-
sponding to IFN (12-14). Israel et al. (12) and Korber et al. (13) reported that in
addition to the ICS, the CRE is necessary for responding to IFN. We found, on
the other hand, that the CRE provides a synergistic but auxiliary effect (14). Thus,
it was of interest to study the role of each region of the CRE for responsiveness to
IFN. As seen in Table I, IFN treatment enhanced CAT activity in all CAT con-
structs except for pLd CAT 123. This construct does not have the ICS and is known
to be incapable of responding to IFN (14). The levels ofCAT induction by IFN among
the mutants were, however, somewhat variable. pLd CAT 1AK M72 and pLd CAT
1.4K M86 gave lower induction than the wild-type pLd CAT 1 .4K, whereas the re-
maining two mutants, M13 and M14, were induced to a level comparable to the
wild type. It should be noted that pLd CAT 1 .4K and pLd CAT 123 both initiated
CAT mRNA synthesis at the expected RNA initiation site both before and after
IFN treatment (14; data not shown). These results suggest that region I and II are
involved in responding to IFN in an auxiliary role.
Discussion
The present study shows that nuclei in murine tissues contain proteins that bind
to discrete subregions ofthe CRE. By using probes corresponding to the entire CRE
as well as region I and region II separately, we have shown that while binding ac-
tivity to region II occurs in tissues, irrespective of class I gene expression, protein
binding to region I is detected only in tissues that express class I genes at relatively
high levels . Region I binding activity was essentially absent in nuclear extracts from
fetal tissues and adult brain where class I gene expression is low or absent. This
correlation suggests that the region I binding activity plays a role in controlling de-
velopmental and tissue-specific expression of class I gene in vivo.
The biochemical nature of region I binding proteins in tissue extracts has not
been studied in detail. Yano et al. (34) isolated from a murine thymoma line a 48-kD
nuclear factor, KBFI, that binds region I. In addition to this protein, there appears
to be another region I binding factor in cultured cell extracts (Israel, A., personal
communication). More recently, Singh et al. (29) cloned a cDNA that encodes a
protein called H-2TF1, capable of binding region I, which is yet distinct from KBF1
in size and binding properties. NFkB that binds to the Igk gene enhancer also binds
to region I (35). NKkB binding activity is constitutively expressed in a B cell-specific
fashion. Thus, region I is capable of binding multiple proteins. It remains to be
determined whether any of the above reported factors representsthe region I binding
seen in this work. Factors that bind region II have not been as extensively studied
as region I binding factors. Although the purified AP-1 protein is reported to bind
to region 11 (23, 24), our results show that the region II binding activity seen in
these extracts does not represent AP-1. Further, we failed to detect binding activity
to AP-1 sequences with extracts prepared from various murine cellscultured in vitro.
Thus, the region II binding activity detected in mouse extracts appears to be rela-
tively specific for the CRE.1318
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ResultsofCAT assays with mutant CREconstructs show that the mutation M86
in region I has a detrimental effect. Mutation M72 in region II also reduced the
enhancer-like activity, albeit to alesser extent . The results indicate that both region
I and region II are capable of enhancing transcription ofclass I genes, but neither
region alone appears to exert a full effect. Thus, it may be postulated that the low
levelofclass I geneexpression in fetaltissues ismediated primarilyby a factor binding
region II of the CRE. At birth there is the additional appearance of a factor that
binds to region I and a concomitant rise in class I mRNA. However, tissue-specific
in vivo regulation appears to be rather complex, and cannot be explained by the
presence or absence ofCRE binding factors alone. Adult spleen extracts show very
low levels ofregion II binding activity, despite having high levels of class I gene ex-
pression. Adult brain extracts show a region II binding activity, but have no detect-
able class I gene expression. Possible explanations include the inhibition ofbinding
to region II DNA invivo bythe chromatin structure(reviewed inreference 36)found
inbrain oradifferent DNAmethylationpattern. Alternatively, transcription ofclass
I gene may be repressed in the brain by a negative trans-acting factor. Repression
of class I gene transcription mediated by the CRE has been noted in undifferen-
tiated F9 embryonal carcinoma cells (9). To date, a trans-acting factor responsible
for the negative regulation of the class I gene in F9 cells has not been identified.
Extracts from tissues consistently failed to reveal a separate binding activity for
region 111, even though region III binding was detected in a majority oftissue cul-
ture cells. This discrepancy is not explained by differences in the procedures for ex-
tract preparation. Protein binding to region III is unlikely to be an artifact oftissue
culture, since the region III sequence is well conserved in the murine CRE and in
thehumancounterpart (37). It is possible that factor bindingto region III isusually
absent in tissues and occurs only transiently under specific physiological conditions
or in particular developmental stages. This may account for the apparent lack of
the enhancer-like activity by region III as detected by mutant pL't CAT 1.4K M13
(Table 1).
In conclusion, nuclear proteins are present in vivo that bind to discrete regions
ofthe CRE. Further, their binding to the CRE enhances transcriptions of the class
I gene, providing evidence that binding ofnuclear proteins to the CRE regulates
class I gene expression in vivo.
Summary
Expression of MHC class I genes varies according to developmental stage and
type of tissues. To study the basis ofclass I gene regulation in tissues in vivo, we
examined binding of nuclear proteins to the conserved cis sequence of the murine
H-2 gene, classIregulatory element (CRE), which contains two independent factor-
binding sites, region I and region II. In gel mobility shift analyses we found that
extracts from adult tissues that express class I genes, such as spleen and liver, had
bindingactivity to region I. In contrast, extracts from brain, which does not express
class I genes, did not show region I binding activity. In addition, fetal tissues that
express class I gene at very low levels, also did not reveal region I binding activity.
Binding activity to region I became detectable during the neonatal period when
class I gene expression sharply increases. Most ofthese tissues showed binding ac-
tivity to region II, irrespective ofclass I gene expression. Although region II con-BURKE ET AL.
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tained a sequence similar to the AP-1 recognition site, AP-1 was not responsible for
the region 11 binding activity detected in this work. These results illustrate a correla-
tion between region I binding activity and developmental and tissue-specific expres-
sion of MHC class I genes.
The CRE exerts an enhancer-like activity in cultured fibroblasts. We evaluated
the significance of each factor binding to CRE . Single 2-bp mutations were intro-
duced into the CRE by site-directed mutagenesis and the ability of each mutant
to elicit the enhancer activity was tested in transient CAT assays. A mutation that
eliminated region I protein binding greatly impaired enhancer activity. A mutation
that eliminated region II binding also caused a lesser but measurableeffect . We con-
clude that region I and region II are both capable of enhancing transcription of the
class I gene. These results indicate that in vivo regulation of MHC class I gene ex-
pression is mediated by binding of trans-acting factors to the CRE.
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Stewart and Mr. K. Phimmascone for technical assistance. Ms. D. Allor provided expert secre-
tarial work.
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